Skip to main content

Aquestive Therapeutics, Inc.

corporate_fare Company Profile

Aquestive Therapeutics, Inc.

AQST·NASDAQ·Life Sciences·CIK 0001398733

Aquestive is a pharmaceutical company focused on developing medicines using innovative science and delivery technologies. The company aims to provide alternatives to invasive standard-of-care therapies by delivering complex molecules through non-invasive administrations. Aquestive is advancing Anaphylm™, a late-stage non-device based epinephrine prodrug product candidate for severe allergic reactions, including anaphylaxis, and its AdrenaVerse™ epinephrine prodrug pipeline platform. Aquestive has four licensed commercialized products, which are marketed globally by its licensees. The company is the exclusive manufacturer of these licensed products. Aquestive also collaborates with other pharmaceutical companies, utilizing proprietary technologies such as PharmFilm®, and possesses drug development and commercialization capabilities. The company's production facilities are located in Portage, Indiana, while its corporate headquarters and primary research laboratory facilities are in Warren, New Jersey. Aquestive manufactures licensed products at its facilities and anticipates its current manufacturing capacity is sufficient for commercial quantities of its licensed products and proprietary product candidates in development. Its facilities have been inspected by the FDA, TGA, and DEA, and are subject to inspection by other health agencies, including ANVISA and EMA. Aquestive is a worldwide leader in oral film drug delivery and manufacturing, having historically supplied the substantial majority of the world's oral films for prescription pharmaceutical use and shipped over two billion doses globally. Its PharmFilm® technology uses proprietary polymer compositions as film formers for active pharmaceutical ingredients (APIs) and excipients.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for AQST at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Aquestive Therapeutics Secures $5M Equity Commitment, Extends Anaphylm Regulatory Deadline, and Reports Q4/FY25 Results
  • Aquestive Therapeutics Outlines Anaphylm Resubmission Timeline and 2026 Cash Runway in Investor Presentation
  • Aquestive Therapeutics Receives FDA Complete Response Letter for Anaphylm, Citing Packaging & Administration Deficiencies
  • FDA Identifies Deficiencies in Anaphylm NDA, Potentially Delaying Approval

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$44.55M
Net Income
-$83.78M
Diluted EPS
-$0.78
Op. Cash Flow
-$52.43M
Free Cash Flow
-$52.99M
Gross Profit
$25.99M
Operating Income
-$71.05M
Cash & Equivalents
$121.17M
Debt / Equity
0.00×
Net Margin
-188.1%
Shares Outstanding
122.04M sh
Source: 10-K · filed 2026-03-04 · accession 0001398733-26-000018
$3.52 +1.73% today
52-week range · as of 2026-11-05 $2.93 – $6.85
Market cap
$434.88M
Volume
3.4M (1.3× avg)
3-mo avg 2.5M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AQST - Filings & News (Page 2)

AQST
Mar 04, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.16
Real-time Price: $3.52 info
Change: -$0.640 (-15%) info
Market Cap: $434.879M info
AQST
Feb 26, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.14
Real-time Price: $3.52 info
Change: -$0.621 (-15%) info
Market Cap: $434.879M info
AQST
Feb 02, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.94
Real-time Price: $3.52 info
Change: +$0.580 (+20%) info
Market Cap: $434.879M info
AQST
Jan 09, 2026, 7:18 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.46
Real-time Price: $3.52 info
Change: +$0.060 (+2%) info
Market Cap: $434.879M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets